Effectiveness of combined salmon calcitonin and aspirin therapy for osteoporosis in ovariectomized rats

Wei,Jinsong; Wang,Jian; Gong,Yan; Zeng,Rong

doi:10.3892/mmr.2015.3637

Effectiveness of combined salmon calcitonin and aspirin therapy for osteoporosis in ovariectomized rats

Authors:
- Jinsong Wei
- Jian Wang
- Yan Gong
- Rong Zeng
View Affiliations

Affiliations: Department of Orthopedics, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524001, P.R. China
Published online on: April 16, 2015 https://doi.org/10.3892/mmr.2015.3637
Pages: 1717-1726
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The objective of the present study was to assess the effectiveness of combined salmon calcitonin (sCT) and aspirin [acetylsalicylic acid (ASA)] treatment in an ovariectomized (OVX) rat model of postmenopausal osteoporosis. Following 12 weeks of treatment, therapeutic efficacy was assessed by evaluating changes in the biochemical and biophysical properties of bone (n=8 rats per group). Serological markers of bone metabolism were measured by ELISA; bone mineral densities (BMD) by dual energy X‑ray absorptiometry; bone biomechanics of the femur and lumbar vertebrae by three‑point stress test; trabecular bone morphology of lumbar vertebrae by hematoxylin and eosin staining; messenger RNA expression levels of osteoprotegerin (OPG) and receptor activator of nuclear factor κB ligand (RANKL) in bone marrow cells by reverse transcription‑quantitative polymerase chain reaction and OPG and RANKL protein expression levels in the proximal tibia were analyzed by immunohistochemistry. Compared with treatment by sCT or ASA alone, combined treatment (sCT+ASA) increased BMD, improved femur bone strength, normalized trabecular network architecture and morphology, and increased mRNA and protein expression of OPG, while reducing the expression of RANKL. Collectively, these results demonstrated that combined treatment (sCT+ASA) of osteoporotic symptoms in OVX rats was more effective than treatment with sCT or ASA alone. Furthermore, these two drugs appeared to alter the expression of two distinct factors in the OPG/RANKL/RANK system, suggesting that their effects may be synergistic. Since sCT and ASA are currently approved for use in humans, the results of the present study suggest that the safety and efficacy of sCT+ASA combined therapy for post‑menopausal osteoporosis should be assessed in clinical trials.

View Figures

View References

1	Raisz LG: Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 115:3318–3325. 2005. View Article : Google Scholar : PubMed/NCBI
2	Liu XH, Kirschenbaum A, Yao S and Levine AC: Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system. Ann NY Acad Sci. 1068:225–233. 2006. View Article : Google Scholar : PubMed/NCBI
3	Boyce BF and Xing L: Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 473:139–146. 2008. View Article : Google Scholar : PubMed/NCBI
4	Udagawa N, Takahashi N, Akatsu T, et al: Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA. 87:7260–7264. 1990. View Article : Google Scholar : PubMed/NCBI
5	Kung YY, Felge U, Sarosi I, et al: Activated T cells regulate bone loss and join destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 402:304–309. 1999. View Article : Google Scholar
6	Simonet WS, Lacey DL, Dunstan CR, et al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89:309–319. 1997. View Article : Google Scholar : PubMed/NCBI
7	Jacobs HS: Postmenopausal hormone replacement therapy and breast cancer. Medscape Women’s Health. 5:E22000.
8	Grady D, Wenger NK, Herrington D, et al: Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The heart and estrogen/progestin replacement study. Ann Intern Med. 132:689–696. 2000. View Article : Google Scholar : PubMed/NCBI
9	Rossouw JE, Anderson GL, Prentice RL, et al Writing Group for the Women’ Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 288:321–333. 2002. View Article : Google Scholar : PubMed/NCBI
10	Luckman SP, Hughes DE, Coxon FP, et al: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 13:581–589. 1998. View Article : Google Scholar : PubMed/NCBI
11	Pechalova P, Bakardjiev A, Zaprianov Z, et al: Bisphosphonate-associated osteonecrosis of the jaws – report of three cases in Bulgaria and review of the literature. Acta Clin Croat. 50:273–279. 2011.
12	Andreotti G, Méndez BL, Amodeo P, et al: Structural determinants of salmon calcitonin bioactivity: The role of the Leu-based amphipathic alpha-helix. J Biol Chem. 281:24193–24203. 2006. View Article : Google Scholar : PubMed/NCBI
13	Shen Y, Li M and Wronski TJ: Calcitonin provides complete protection against cancellous bone loss in the femoral neck of ovariectomized rats. Calcif Tissue Int. 60:457–461. 1997. View Article : Google Scholar : PubMed/NCBI
14	Ogawa K, Hori M, Takao R and Sakurada T: Effects of combined elcatonin and alendronate treatment on the architecture and strength of bone in ovariectomized rats. J Bone Miner Metab. 23:351–358. 2005. View Article : Google Scholar : PubMed/NCBI
15	Reginster JY: Management of high turnover osteoporosis with calcitonin. Bone. 13(Suppl 2): S37–S40. 1992. View Article : Google Scholar : PubMed/NCBI
16	Solheim LF, Rönningen H and Langeland N: Effects of acetylsalicylic acid on heterotopic bone resorption and formation in rats. Arch Orthop Trauma Surg. 105:142–145. 1986. View Article : Google Scholar : PubMed/NCBI
17	Carbone LD, Tylavsky FA, Cauley JA, et al: Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res. 18:1795–1802. 2003. View Article : Google Scholar : PubMed/NCBI
18	Vestergaard P, Hermann P, Jensen JE, et al: Effects of paracetamol, nonsteroidal anti-inflammatory drugs, acetylsalicylic acid and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS). Osteoporos Int. 23:1255–1265. 2012. View Article : Google Scholar
19	Kataoka T, Shinohara N, Takayama H, et al: Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol. 156:3678–3686. 1996.PubMed/NCBI
20	Yamaza T, Miura Y, Bi Y, et al: Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS One. 3:e26152008. View Article : Google Scholar : PubMed/NCBI
21	Lin SK, Kok SH, Kuo MY, et al: Sequential expressions of MMP-1, TIMP-1, IL-6, and COX-2 genes in induced periapical lesions in rats. Eur J Oral Sci. 110:246–253. 2002. View Article : Google Scholar : PubMed/NCBI
22	Frost HM and Jee WS: On the rat model of human osteopenias and osteoporoses. Bone Miner. 18:227–236. 1992. View Article : Google Scholar : PubMed/NCBI
23	Cui L, Wu T, Liu YY, et al: Tanshinone prevents cancellous bone loss induced by ovariectomy in rats. Acta Pharmacol Sin. 25:678–684. 2004.PubMed/NCBI
24	Van Poznak C, Cross SS, Saggese M, et al: Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL) and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours. J Clin Pathol. 59:56–63. 2006. View Article : Google Scholar : PubMed/NCBI
25	Lowry F: FDA panel says to stop marketing salmon calcitonin for osteoporosis. Medscape Medical News. March 6–2013, http://www.medscape.com/viewarticle/780323. Accessed August 10, 2013.
26	Byrne P: Quality and outcomes framework indicators for osteoporosis. Prescriber. 23:14–22. 2012. View Article : Google Scholar
27	de Freitas PH, Hasegawa T, Takeda S, et al: Eldecalcitol, a second-generation vitamin D analog, drives bone minimodeling and reduces osteoclastic number in trabecular bone of ovariectomized rats. Bone. 49:335–342. 2011. View Article : Google Scholar : PubMed/NCBI
28	Kanis JA, Melton LJ III, Christiansen C, et al: The diagnosis of osteoporosis. J Bone Miner Res. 9:1137–1141. 1994. View Article : Google Scholar : PubMed/NCBI
29	Rico H, Valencia MJ, Villa LF, et al: Calcitonin versus clodronate in the prevention of ovariectomy-induced osteopenia in rats. Clin Rheumatol. 19:47–50. 2000.PubMed/NCBI
30	Kavuncu V, Sahin S, Baydas G, et al: A comparison of estrogen and two different doses of calcitonin in ovariectomized rats. Yonsei Med J. 44:508–516. 2003. View Article : Google Scholar : PubMed/NCBI
31	Friedman AW: Important determinants of bone strength: beyond bone mineral density. J Clin Rheumatol. 12:70–77. 2006. View Article : Google Scholar : PubMed/NCBI
32	NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy: Osteoporosis prevention, diagnosis, and therapy. JAMA. 285:785–795. 2001. View Article : Google Scholar : PubMed/NCBI
33	Li XJ, Jee WS and Li YL: Flurbiprofen enhances growth and cancellous and cortical bone accumulation in rapidly growing long bones. Bone. 10:35–44. 1989. View Article : Google Scholar : PubMed/NCBI
34	Dempster DW, Birchman R, Xu R, et al: Temporal changes in cancellous bone structure of rats immediately after ovariectomy. Bone. 16:157–161. 1995. View Article : Google Scholar : PubMed/NCBI
35	Li M, Shen Y, Burton KW, et al: A comparison of the skeletal effects of intermittent and continuous administration of calcitonin in ovariectomized rats. Bone. 18:375–380. 1996. View Article : Google Scholar : PubMed/NCBI
36	van der Linden JC, Homminga J, Verhaar JA and Weinans H: Mechanical consequences of bone loss in cancellous bone. J Bone Miner Res. 16:457–465. 2001. View Article : Google Scholar : PubMed/NCBI
37	Zioupos P, Cook RB and Hutchinson JR: Some basic relationships between density values in cancellous and cortical bone. J Biomech. 41:1961–1968. 2008. View Article : Google Scholar : PubMed/NCBI
38	Lee J and Vasikaran S: Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med. 32:105–112. 2012. View Article : Google Scholar : PubMed/NCBI
39	Yasumizu T, Okuno T, Fukada Y and Hoshi K: Age-related changes in bone mineral density and serum bone-related proteins in premenopausal and postmenopausal Japanese women. Endocr J. 47:103–109. 2000. View Article : Google Scholar : PubMed/NCBI
40	Trouvin AP and Goëb V: Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging. 5:345–354. 2010.
41	Liu HY, Wu AT, Tsai CY, et al: The balance between adipogenesis and osteogenesis in bone regeneration by platelet-rich plasma for age-related osteoporosis. Biomaterials. 32:6773–6780. 2011. View Article : Google Scholar : PubMed/NCBI
42	Villa I, Mrak E, Rubinacci A, et al: CGRP inhibits osteoprotegerin production in human osteoblast-like cells via cAMP/PKA-dependent pathway. Am J Physiol Cell Physiol. 291:C529–C537. 2006. View Article : Google Scholar : PubMed/NCBI
43	Huebner AK, Schinke T, Priemel M, et al: Calcitonin deficiency in mice progressively results in high bone turnover. J Bone Miner Res. 21:1924–1934. 2006. View Article : Google Scholar : PubMed/NCBI
44	Chen WH, Zeng R, Lo WC, et al: The role of the ERK1/2 pathway as an alternative to the aging-diminished cyclic AMP pathway in calcitonin-mediated chondrogenesis in human nucleus pulposus. Biomaterials. 33:8256–8264. 2012. View Article : Google Scholar : PubMed/NCBI
45	Xu J, Kauther MD, Hartl J, et al: Effects of alpha-calcitonin gene-related peptide on osteoprotegerin and receptor activator of nuclear factor-κB ligand expression in MG-63 osteoblast-like cells exposed to polyethylene particles. J Orthop Surg Res. 5:832010. View Article : Google Scholar
46	Downey ME, Holliday LS, Aguirre JI and Wronski TJ: In vitro and in vivo evidence for stimulation of bone resorption by an EP4 receptor agonist and basic fibroblast growth factor: Implications for their efficacy as bone anabolic agents. Bone. 44:266–274. 2009. View Article : Google Scholar
47	Raisz LG: Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and disease. Am J Med. 110(Suppl 3A): 43S–45S. 2001. View Article : Google Scholar : PubMed/NCBI